All Screens Lead to Polo-like kinase 1: A Central Node in Cancer Therapeutics and Resistance. (PubMed, Pharmacol Res) - May 20, 2026 - "Emerging evidence supports synergistic potential of new-generation PLK1 inhibitors, such as Onvansertib, with chemo- and immune-therapies. This mini-review and perspective present current insights on PLK1 overexpression and its mechanistic impact on cancer aggressiveness and therapy resistance. We highlight the need for refined patient stratification and innovative combination regimens to exploit PLK1 inhibition in cancer treatment."
Journal • Review • Oncology • PLK1
|
|
Abdul K Siraj; Edward Hitti; Khalid S A Khabar; Khawla Al-Kuraya; Maeva Dufies; Norah Al-Souhibani; Otília Menyhárt; Pagès Gilles; Pratheesh K Poyil
|